O1-17. Combining anti TNF-α and vedolizumab in the treatment of inflammatory bowel disease
Lydia C.T. Buer [1, 2] Marte L. Høivik , David J. Warren , Asle W. Medhus  and Bjørn A. Moum [1, 2]
Affiliates:  Department of Gastroenterology, Oslo University Hospita,  Faculty of Medicine, University of Oslo,  Department of Medical Biochemistry, Oslo University Hospital.
Anti-tumour necrosis factor α (anti TNF-α) is important in the treatment of inflammatory bowel disease, but some patients experience only partial response. In these patients, a combination of anti TNF-α and vedolizumab (VDZ) may act as bridging until full VDZ effect occurs. At present, clinical data on combination treatment with anti TNF-α and VDZ are not available. The aim of this case series was to evaluate safety and clinical response of combination therapy with anti TNF-α and VDZ in clinical practice.
All patients starting on combination treatment with anti TNF-α and VDZ during November 2015 to July 2016 were followed prospectively for at least 12 months.
Six patients with ulcerative colitis and four with Crohn’s disease received combination treatment. They were followed for a median of 17 (12-20) months. No more adverse events than expected on anti TNF-α alone were observed during combination treatment. At the end of follow up, all patients were in clinical remission and eight could discontinue anti TNF-α and receive VDZ in monotherapy.
Our findings suggest that combination treatment with anti TNF-α and VDZ is safe and might represent a long-term treatment option in selected patients.